Scarica l'app Stockscreener
39.51
2.78%
1.07
Pre-mercato:
38.74
-0.77
-1.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$38.44
Aprire:
$38.46
Volume 24 ore:
3.13M
Relative Volume:
1.11
Capitalizzazione di mercato:
$10.64B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
22.32
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
-0.30%
1M Prestazione:
+0.92%
6M Prestazione:
+10.55%
1 anno Prestazione:
+50.57%
Intervallo 1D:
$38.18
$39.90
Intervallo di 1 settimana:
$37.52
$39.90
Portata 52W:
$26.06
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
39.51 | 10.35B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Key metrics from Exelixis Inc.’s quarterly dataQuarterly Investment Review & Daily Growth Stock Tips - newser.com
Analyzing drawdowns of Exelixis Inc. with statistical tools2025 Analyst Calls & Weekly Top Gainers Alerts - newser.com
Truist Securities reiterates Buy rating on Exelixis stock ahead of ESMO 2025 - Investing.com Canada
The Ultimate Biotech Stock to Buy With $50 Right Now - The Globe and Mail
The Ultimate Biotech Stock to Buy With $50 Right Now - The Motley Fool
How Exelixis Inc. stock trades during market volatilityWeekly Profit Recap & Fast Moving Stock Trade Plans - newser.com
How to integrate Exelixis Inc. into portfolio analysis tools2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
Detecting price anomalies in Exelixis Inc. with AIPortfolio Risk Summary & Entry and Exit Point Strategies - newser.com
Is this a good reentry point in Exelixis Inc.Options Play & High Win Rate Trade Tips - newser.com
Best data tools to analyze Exelixis Inc. stockMarket Movers & Fast Exit Strategy with Risk Control - newser.com
What recovery options are there for Exelixis Inc.2025 Key Lessons & Fast Gain Stock Tips - newser.com
Will earnings trigger a reversal in Exelixis Inc.Insider Buying & AI Based Buy/Sell Signal Reports - newser.com
Chart overlay techniques for tracking Exelixis Inc.July 2025 WrapUp & AI Powered Buy/Sell Recommendations - newser.com
Real time breakdown of Exelixis Inc. stock performanceJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Exelixis, Inc. (EXEL) Stock Analysis: Unlocking A 16% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Is Exelixis Inc. (EX9) stock worth buying before Fed actionDip Buying & Long-Term Capital Growth Strategies - newser.com
Historical volatility pattern of Exelixis Inc. visualized2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Is Upward Earnings Estimate Momentum Altering The Investment Case For Exelixis (EXEL)? - Yahoo Finance
Exelixis' (NASDAQ:EXEL) Earnings Growth Rate Lags the 35% CAGR Delivered to Shareholders - 富途牛牛
Is Exelixis Inc. forming a bottoming baseJuly 2025 Drop Watch & Weekly Setup with High ROI Potential - newser.com
Order flow analysis tools used on Exelixis Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
Is Exelixis Inc. (EX9) stock considered safe havenMarket Activity Report & Low Risk Entry Point Guides - newser.com
Can Exelixis Inc. stock sustain market leadership2025 Key Highlights & Weekly High Return Opportunities - newser.com
What analyst consensus says on Exelixis Inc. stock2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com
Advanced analytics toolkit walkthrough for Exelixis Inc.Buy Signal & Free Community Supported Trade Ideas - newser.com
Is Exelixis Inc. (EX9) stock supported by strong fundamentalsJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - sharewise.com
What does recent volatility data suggest for Exelixis Inc.Earnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
Exelixis Inc. stock volume spike explainedJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - newser.com
Automated trading signals detected on Exelixis Inc.Market Growth Review & AI Driven Price Forecasts - newser.com
Pattern recognition hints at Exelixis Inc. upside2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
How Exelixis Inc. stock performs in stagflationPortfolio Return Report & Weekly High Momentum Picks - newser.com
Exelixis shuttering Pennsylvania site, laying off 130 employees - MSN
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.15%
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):